Serum alpha1-antitrypsin in patients with lung cancer or abnormal sputum cytology
Open Access
- 1 October 1976
- Vol. 38 (4) , 1655-1657
- https://doi.org/10.1002/1097-0142(197610)38:4<1655::aid-cncr2820380435>3.0.co;2-f
Abstract
Serum alpha1‐antitrypsin Pi types and trypsin inhibitory capacity (TIC) were measured in 72 patients with lung cancer and in 196 patients with abnormal sputum cytology but no clinical evidence of lung cancer to determine if a genetic deficiency of alpha1‐antitrypsin (AAT) predisposes to lung cancer. The distributions of Pi types in these two groups of patients and healthy adults are similar. Serum TIC and AAT concentrations are elevated in lung cancer patients. However, patients with abnormal sputum cytology and no clinical lung cancer have normal levels of serum TIC and AAT. A genetic deficiency of AAT probably does not produce a state of increased susceptibility to the carcinogenic effects of respiratory carcinogens such as tobacco smoke.This publication has 7 references indexed in Scilit:
- The preparation and properties of two new chromogenic substrates of trypsinPublished by Elsevier ,2004
- Elevated alpha1-antitrypsin serum levels in lung cancer patientsCancer, 1974
- Alpha1-Antitrypsin DeficiencyMedical Clinics of North America, 1973
- Smoking and Chronic Obstructive Lung Disease in Alpha1-Antitrypsin DeficiencyChest, 1971
- The polymorphism of “prealbumins” and α1-antitrypsin in human seraClinica Chimica Acta; International Journal of Clinical Chemistry, 1967
- The Electrophoretic α;1-Globulin Pattern of Serum in α;1-Antitrypsin DeficiencyScandinavian Journal of Clinical and Laboratory Investigation, 1963
- The Electrophoretic α;1-Globulin Pattern of Serum in α;1-Antitrypsin DeficiencyScandinavian Journal of Clinical and Laboratory Investigation, 1963